Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Ibnsina Pharma's Revenue for the
three
months ended in Mar. 2026 was E£20,501 Mil. Ibnsina Pharma's average Accounts Receivable for the
three
months ended in Mar. 2026 was E£21,539 Mil.
Hence, Ibnsina Pharma's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.95.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Ibnsina Pharma Receivables Turnover Related Terms
Ibnsina Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Ibnsina Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:ISPH vs MCK, COR, CAH: Receivables Turnover Comparison
For the Medical Distribution subindustry, Ibnsina Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibnsina Pharma Receivables Turnover vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Ibnsina Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ibnsina Pharma (CAI:ISPH) has a Receivables Turnover of 0.95 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ibnsina Pharma and its competitors. According to the industry distribution chart, Ibnsina Pharma ranks #74 out of 118 companies in the Medical Distribution industry, placing it in the top 62.7%.
Is Ibnsina Pharma's Receivables Turnover too high?
Ibnsina Pharma's current Receivables Turnover is 0.95. The Medical Distribution industry median Receivables Turnover is 4.72. Ibnsina Pharma's value of 0.95 is 79.9% below this industry median. Based on the distribution chart, Ibnsina Pharma ranks #74 out of 118 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ibnsina Pharma has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Receivables Turnover compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #74 out of 118 companies for Receivables Turnover. This places Ibnsina Pharma in the lower half of its industry. The industry median Receivables Turnover is 4.72. Ibnsina Pharma's value of 0.95 is 79.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Distribution company?
The median Receivables Turnover among Medical Distribution companies is 4.72, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibnsina Pharma's current Receivables Turnover of 0.95 is 79.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ibnsina Pharma and its competitors. For the Medical Distribution industry, the median Receivables Turnover is 4.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current Receivables Turnover is 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.70, compared to a current price of E£13.02 — trading 21.7% above its estimated fair value. The current Receivables Turnover is 0.95 and 79.9% below the Medical Distribution industry median of 4.72. Ibnsina Pharma's overall GF Score™ is 83/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Receivables Turnover is 0.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£13.02 is trading 21.7% above its estimated GF Value™ of E£10.70.
GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.
Key valuation signals for CAI:ISPH:
Receivables Turnover: 0.95
GF Value™: E£10.70 vs. price of E£13.02 (21.7% above fair value)
Industry Position: 79.9% below the Medical Distribution median (#74 of 118)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
83GF Score
Get the complete analysis for CAI:ISPH
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
